ARS Pharmaceuticals, Inc. (SPRY) Cash Flow Statement
ARS Pharmaceuticals, Inc. (SPRY) generated -$196.4M of operating cash flow over the twelve months to 2026-06-30, spent $197000 on capital expenditure and had free cash flow of -$196.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SPRYARS Pharmaceuticals, Inc.Follow SPRY — free
—
Price chart with a free account
- Market cap
- 400.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating cash flow | -40.1 | -59.3 | 13.5 | -170.9 | -196.4 | |
| Capital expenditure | 0.2 | 0.2 | 0.6 | 0.3 | -0.2 | |
| Free cash flow | -40.3 | -59.4 | 13.0 | -171.2 | -196.6 | |
| Stock-based compensation | 5.8 | 9.2 | 14.5 | 22.1 | — |
USD millions · SEC XBRL
ARS Pharmaceuticals, Inc. — questions
- What is ARS Pharmaceuticals, Inc.'s operating cash flow?
- -$196.4M over the twelve months to 2026-06-30.
- How much does ARS Pharmaceuticals, Inc. spend on capital expenditure?
- $197000 over the twelve months to 2026-06-30.
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- -$196.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from ARS Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.